| Generic Name | Prochlorperazine |
|---|---|
| Drug Class | Phenothiazine Derivative (Dopamine D₂ Receptor Antagonist) |
| Indications |
|
| Mechanism of Action | Blocks dopamine (D₂) receptors in the chemoreceptor trigger zone of the brain, suppressing nausea and vomiting. Also has mild anticholinergic and antihistaminic effects. |
| Available Forms & Strengths | • Tablet: 5 mg, 10 mg • Buccal tablet: 3 mg • Injection: 12.5 mg/mL |
| Dosage | Adults: 5–10 mg 2–3 times daily Children: 0.1–0.15 mg/kg per dose (specialist advice) |
| Route | Oral, Buccal, IM, IV |
| Common Side Effects |
|
| Serious Adverse Effects | Extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation |
| Contraindications | • Parkinson’s disease • CNS depression • Bone marrow suppression • Pheochromocytoma |
| Precautions | • Children and elderly (↑ EPS risk) • Epilepsy • Cardiovascular disease |
| Drug Interactions | • CNS depressants • Antipsychotics (↑ EPS risk) • QT-prolonging drugs |
| Pregnancy & Lactation | Pregnancy: Use only if benefit outweighs risk Lactation: Avoid or use with caution |
| Storage | Store below 30°C, protect from light |
| References | BNF | BNF for Children | Nelson Textbook of Pediatrics |